Protagonist Therapeutics, Inc. (PTGX)

28,32 +0,05 (+0,18%) A partir del 03:21PM EDT. Mercado abierto.

Protagonist Therapeutics, Inc.

7707 Gateway Boulevard
Suite 140
Newark, CA 94560-1160
United States
510 474 0170
https://www.protagonist-inc.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 124

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Dinesh V. Patel Ph.D.	CEO, President, Secretary & Director	1,03M	N/A	1957
Mr. Asif Ali	Executive VP & Chief Financial Officer	631,04k	N/A	1974
Dr. Suneel K. Gupta Ph.D.	Chief Development Officer	719,21k	N/A	1959
Dr. Mark Smythe Ph.D.	Founder & VP Technology	N/A	N/A	1965
Mr. Mohammad Masjedizadeh Ph.D.	Executive VP & Chief Technical Officer	N/A	N/A	N/A
Mr. Matthew M. Gosling	Executive VP & General Counsel	N/A	N/A	1971
Ms. Carena Spivey	Head of HR & Senior VP of Human Resources	N/A	N/A	N/A
Dr. Ashok Bhandari Ph.D.	Executive VP & Chief Drug Discovery and Preclinical Development Officer	N/A	N/A	1964
Mr. Carter J. King	Executive Vice President of Business Development	N/A	N/A	1971
Ms. Abha Bommireddi	Executive Vice President of Portfolio & Program Management	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Gobierno corporativo

El ISS Governance QualityScore de Protagonist Therapeutics, Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 9; Tablero: 7; Derechos de los accionistas: 7; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.